GSK Gains Lovaza By Acquiring Reliant For $1.65 Billion
This article was originally published in The Pink Sheet Daily
Executive Summary
Addition of the triglyceride treatment will complement GSK’s Coreg CR physician base, company tells “The Pink Sheet” DAILY.